Active ingredients: lenograstim
What it is used for
To reduce the duration of neutropenia and the severity of infections in patients with non-myeloid malignancy who have either undergone autologous or allogeneic bone marrow transplantation or undergone treatment with established cytotoxic chemotherapy. To reduce the incidence of infection associated with established cytotoxic chemotherapy. To mobilise peripheral blood progenitor cells (PBPCs) either with Granocyte alone, or after myelosuppresive chemotherapy, in order to accelerate haematopoietic recovery by infusion of such cells, after myelosuppressive or myeloablative therapy in patients with non-myeloid malignancies. Granocyte is also indicated to accelerate the engraftment of these cells after their infusion. To mobilise peripheral blood progenitor cells (PBPCs) in healthy donors. In the treatment of severe congenital neutropenia.
How to take it
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
- The way to take this medicine: Subcutaneous
- Store below 30 degrees Celsius
- Do Not use if Colour Changes
- Lifetime is 30 Months.
Always read the label. If symptoms persist see your healthcare professional.
White cake (lyophilised powder) in a glass vial with rubber stoppers and flip off cap
Do I need a prescription?
This medicine is available from a pharmacist and requires a prescription. It is
Pregnant or planning a pregnancy?
For the active ingredient lenograstim
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
For side effects, taking other medicines and more
Download consumer medicine information leaflet (pdf)